Clinical trials: Placebo Response
Acute Kidney Injury Due to Sepsis
Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury
The purpose of this study was to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a…
- Trial name
- NCT05507437
- Testing
- TIN816 70 mg lyophilisate powder
- Where
- 7 sites in Belgium, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19 Vaccination
RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), for use as an adjunct to vaccination for COVID-19 in a…
- Trial name
- MACH19 (NCT04951336)
- Testing
- FoTv
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- REASSURE (NCT01377012)
- Testing
- Secukinumab (AIN457)
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 637 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate…
- Trial name
- LADYBUG (NCT04577781)
- Testing
- GLPG3970
- Where
- 9 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 28 people
- Sponsor
- Lakefront Biotherapeutics NV
Sepsis, Pneumonia
Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System
High mortality associated with sepsis and Multiple Organ Dysfunction Syndrome (MODS) calls for alternative, individualized therapies in selected patients that might benefit form specific interventions.
- Conditions
- Sepsis, Pneumonia, Gram-Negative Bacteria Infection, Multiple Organ Failure
- Trial name
- INCLASS (NCT03345992)
- Testing
- Clarithromycin, Water for injection
- Where
- 12 sites in Belgium, Greece
- Volunteers
- 110 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Asthma
A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise
This study is intended to determine the dose response and duration of action of GSK2190915 in mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.
- Trial name
- NCT00812929
- Testing
- GSK2190915
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4995819 as adjunctive therapy in patients with major depressive disorder having inadequate…
- Trial name
- NCT01457677
- Testing
- RO4995819
- Where
- 92 sites in United States, Austria and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
Chronic Pain, Central Sensitisation
The Effect of Griffonia Simplicifolia on Pain Intensity, Central and Peripheral Sensitization, Painmodulation in Healthy Volunteers
This planned study is based on a randomized, placebo-controlled cross-over design. Griffonia simplicifolia contains the serotonin-precursor 5-hydroxytryptophan (5-HTP), an endogenous amino acid.
- Conditions
- Chronic Pain, Central Sensitisation, Peripheral Sensitization, Neuroinflammatory Response
- Trial name
- NCT06893822
- Testing
- Griffonia simplicifolia
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Infection Associated With Catheter, Bacteremia
Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature Neonates
Appropriate delivery of adequate nutrition and medications in premature infants often requires central venous access in the form of a special IV called a PICC (peripherally inserted central catheter).
- Conditions
- Infection Associated With Catheter, Bacteremia, Sepsis
- Trial name
- NCT01365312
- Testing
- Ethanol lock, Heparinized saline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- East Carolina University
Rhinitis, Allergic, Seasonal
Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever
The purpose of this study is to see if a new nasal spray can reduce the signs and symptoms of allergic rhinitis (hayfever). Subjects' participation in the study will last approximately 4 to 6 weeks, and each of three study visits…
- Trial name
- NCT01500629
- Testing
- C-1266-7
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
PRA-216 COPD Safety and Biomarker Study
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT07730281
- Testing
- PRA-216
- Where
- 5 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Prana Therapies Inc
Alzheimer's Disease
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the brain metabolic response using Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), safety, tolerability and pharmacokinetics of AGN-242071 in patients with mild to moderate Alzheimer's…
- Trial name
- NCT03316898
- Testing
- AGN-242071, Donepezil, Memantine
- Where
- 6 sites in United States
- Sponsor
- Allergan
Osteoarthritis of the Knee
Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis
The objective of this study was to explore the efficacy, dose-response and safety of PG201 tablet in Korean patients with osteoarthritis.
- Trial name
- NCT01122485
- Testing
- PG201
- Sponsor
- Helixmith Co., Ltd.
Schizophrenia
A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia
- Trial name
- NCT00316238
- Testing
- olanzapine-RAIM
- Where
- 15 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Healthy
The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Healthy Humans. A Dose-response Study
The purpose of this study is to investigate the effect of different doses of sodium nitrite infusion in 12 healthy subjects. The effects on renal handling of nitrite, nitrate, sodium and water, plasma concentrations of vasoactive…
- Trial name
- NCT02078908
- Testing
- Sodium nitrite, 40 micrograms/kg/hour, Sodium nitrite, 120 micrograms/kg/hour, Sodium nitrite, 240 micrograms/kg/hour
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Erling Bjerregaard Pedersen
Autism Spectrum Disorder
Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls
This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication.
- Trial name
- OxySPECTRUM (NCT07555132)
- Testing
- MDMA
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Placebo Effect, Drug Half Life
The Placebo Effect May Involve Modulating Drug Bioavailability
The total effect of a medication is the sum of its drug effect, placebo effect (meaning response of placebo), and their interaction.
- Conditions
- Placebo Effect, Drug Half Life, Pharmacokinetics
- Trial name
- NCT01501747
- Testing
- Caffeine, paracetamol, cephalexin, or ibuprofen
- Where
- Saudi Arabia
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- King Faisal Specialist Hospital & Research Center
Rheumatoid Arthritis
GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis
Part A: 30 patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will receive once daily two capsules containing either GLPG0259 (25 mg/capsule) or matching placebo, for 12 weeks.
- Trial name
- NCT01211249
- Testing
- GLPG0259 oral capsule, GLPG0259 (Part B)
- Where
- 32 sites in Belgium, Netherlands and 3 more
- Volunteers
- 30 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to…
- Trial name
- SELECT-NEXT (NCT02675426)
- Testing
- Upadacitinib
- Where
- 167 sites in United States, Argentina and 36 more
- Volunteers
- 661 people
- Sponsor
- AbbVie
Schizophrenia
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
- Trial name
- NCT00580125
- Testing
- PF-00217830, Aripiprazole
- Where
- 26 sites in United States, India and 2 more
- Volunteers
- 164 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.